Navigation Links
Precision Antibody Expands Antibody Characterization Services

COLUMBIA, Md., March 15, 2012 /PRNewswire-iReach/ -- Precision Antibody, a market leader in contract antibody services, announced today that they have expanded their antibody characterization services to include Fortebio's  Octet RED96™ system, a multi-functional, label-free, real-time binding analysis instrument.  

Since 2006, Precision Antibody has been providing antibody characterization services using Biacore™ 3000 by GE Healthcare, a Surface Plasmon Resonance (SPR) based real time binding kinetic analysis machine.  We are now proud to announce the addition of the Octet RED96 from ForteBio to enhance our cutting edge antibody characterization capabilities and services. The Octet Red96 uses Bio-Layer Interferometry (BLI) technology for the detection of label-free real time molecular interaction analysis.

The Octet Red96 can perform up to 8 label-free binding assays at one time, allowing high throughput antibody screening and characterization.   The technology is fully integrated into Precision Antibody's custom monoclonal antibody development platform to aid the selection of suitable application-specific clones otherwise missed in a conventional EIA based screening format.

Octet Red96 can be used for the screening of monoclonal antibodies using unlabeled free antigen in solution, antibody quantification, affinity based antibody ranking, epitope binning, full binding kinetic analysis, and more.  Binding kinetic analyses can be performed with molecules as small as 150 Dalton.

"We are excited to offer an additional cutting edge technology to our customers. Together with our state-of-the-art monoclonal antibody development platform technology, we continue to deliver the highest quality antibodies to our customers" says Jun Hayashi, Ph.D., the VP of Precision Antibody.

About Precision Antibody (

Precision Antibody™ provides customized, high-affinity monoclonal and polyclonal antibodies to pharmaceutical and biotechnology companies as well as to academic, government, and nonprofit research institutions.  Precision Antibody™ develops antibodies for the use in research and discovery, for the development of preclinical therapeutic and diagnostic targets, and for QC and PK studies. The company's products and services are based on a proprietary antibody discovery and development platform technology that enables rapid development of target-specific, high-affinity antibodies. Precision Antibody™ provides one-stop service for antibody development, characterization (isotype and affinity determination), purification/production (from pilot to large scale), and conjugation, as well as stable cell line development and hybridoma cell banking. Precision Antibody™ is a wholly owned service division of A&G Pharmaceutical, Inc. ( ) and is based in Columbia, MD.

About Octet RED96™ & Biacore™

Octet RED96™ is a registered trademark of ForteBio, Inc.  Precision Antibody is not affiliated with ForteBio, Inc. products or services.  Biacore™ is a registered trademark of GE Healthcare. Precision Antibody is not affiliated with GE Healthcare products or services.

Media Contact: Michael Keefe, Precision Antibody, 410-884-4100,

News distributed by PR Newswire iReach:

SOURCE Precision Antibody
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Precision Therapeutics Enhances Their Straightforward Approach to Personalizing Cancer Care
2. Cogmedix Provides High-Precision Subassembly for LensAR Revolutionary Refractive Laser
3. Boston Scientific Receives FDA Approval for New Infinion™ 16 Percutaneous Lead for Precision Plus™ Spinal Cord Stimulator System
4. TIs new MSP430™ microcontrollers enable more performance and higher precision in home automation, industrial and portable medical applications
5. Upgraded ACCF/ AHA/ SCAI Guidelines Reinforce Benefits of Volcanos Precision Guided Therapy Technologies
6. TechPrecision Corporations WCMC Division Adds Second Sapphire Customer
7. Vapotherm® Announces FDA Clearance for Precision Flow® Heliox System
8. FDA Awards Precision Antibody Contract to Develop Monoclonal Antibodies for Influenza Vaccine Potency Assays
9. Precision Therapeutics Named on Inc. 500
10. 5000 2011 List and Recognized for Achievements in Personalized Medicine Industry
11. Precision Therapeutics Presents Clinical Study Emphasizing the Role of ChemoFx® in Directing Chemotherapy in Gynecological Cancers
Post Your Comments:
(Date:6/24/2016)... , June 24, 2016 Research and ... Market for Companion Diagnostic Tests" report to their offering. ... for Companion Diagnostics The World Market for ... personalized medicine diagnostics. Market analysis in the report includes the ... Market (In Vitro Diagnostic Kits) by Region (N. America, EU, ...
(Date:6/24/2016)... Belgium , June 24, 2016 ... today announced the appointment of Dr. Edward ... as a Non-Executive Director, effective June 23, 2016.Dr. ... Compensation and Nominations and Governance Committees.  As a ... will provide independent expertise and strategic counsel to ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... that was developed to enhance the health of felines. The formula is all-natural and ... main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, ... Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. ... skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern ... Laude and his M.D from the David Geffen School of Medicine at UCLA. He ... Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
Breaking Medicine News(10 mins):